4.19 USD
+0.02 (+0.48%)
Overall NEUP gets a fundamental rating of 3 out of 10. We evaluated NEUP against 525 industry peers in the Biotechnology industry. NEUP scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. NEUP is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
- In the past year NEUP has reported negative net income.
- NEUP had a positive operating cash flow in the past year.
- In the past 5 years NEUP always reported negative net income.
- NEUP had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
- NEUP has a Return On Assets of -1.29%. This is amongst the best in the industry. NEUP outperforms 88.00% of its industry peers.
- NEUP has a Return On Equity of -1.95%. This is amongst the best in the industry. NEUP outperforms 89.52% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1.29% | ||
| ROE | -1.95% | ||
| ROIC | N/A |
ROA(3y)-44.06%
ROA(5y)-36.63%
ROE(3y)-62.56%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- NEUP does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- NEUP does not have a ROIC to compare to the WACC, probably because it is not profitable.
- Compared to 1 year ago, NEUP has less shares outstanding
- The number of shares outstanding for NEUP has been reduced compared to 5 years ago.
- The debt/assets ratio for NEUP has been reduced compared to a year ago.
2.2 Solvency
- Based on the Altman-Z score of -6.46, we must say that NEUP is in the distress zone and has some risk of bankruptcy.
- Looking at the Altman-Z score, with a value of -6.46, NEUP is doing worse than 64.57% of the companies in the same industry.
- The Debt to FCF ratio of NEUP is 0.43, which is an excellent value as it means it would take NEUP, only 0.43 years of fcf income to pay off all of its debts.
- NEUP's Debt to FCF ratio of 0.43 is amongst the best of the industry. NEUP outperforms 95.24% of its industry peers.
- NEUP has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
- NEUP has a Debt to Equity ratio (0.00) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0.43 | ||
| Altman-Z | -6.46 |
ROIC/WACCN/A
WACC8.93%
2.3 Liquidity
- NEUP has a Current Ratio of 3.56. This indicates that NEUP is financially healthy and has no problem in meeting its short term obligations.
- With a Current ratio value of 3.56, NEUP perfoms like the industry average, outperforming 42.29% of the companies in the same industry.
- A Quick Ratio of 3.56 indicates that NEUP has no problem at all paying its short term obligations.
- NEUP has a Quick ratio (3.56) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.56 | ||
| Quick Ratio | 3.56 |
3. Growth
3.1 Past
- The earnings per share for NEUP have decreased strongly by -130.00% in the last year.
- NEUP shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -59.98% yearly.
EPS 1Y (TTM)-130%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)N/A
Revenue growth 3Y-33.45%
Revenue growth 5Y-59.98%
Sales Q2Q%N/A
3.2 Future
- The Earnings Per Share is expected to decrease by -186.38% on average over the next years. This is quite bad
- The Revenue is expected to grow by 14.87% on average over the next years. This is quite good.
EPS Next Y-104017.17%
EPS Next 2Y-3227.34%
EPS Next 3Y165.45%
EPS Next 5Y-186.38%
Revenue Next Year686792%
Revenue Next 2Y4405.1%
Revenue Next 3Y2711.32%
Revenue Next 5Y14.87%
3.3 Evolution
- The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for NEUP. In the last year negative earnings were reported.
- Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NEUP. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
- Based on the Price/Free Cash Flow ratio, NEUP is valued cheaply inside the industry as 90.67% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 292 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- NEUP's earnings are expected to grow with 165.45% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-3227.34%
EPS Next 3Y165.45%
5. Dividend
5.1 Amount
- No dividends for NEUP!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
NEUPHORIA THERAPEUTICS INC / NEUP FAQ
What is the fundamental rating for NEUP stock?
ChartMill assigns a fundamental rating of 3 / 10 to NEUP.
What is the valuation status of NEUPHORIA THERAPEUTICS INC (NEUP) stock?
ChartMill assigns a valuation rating of 2 / 10 to NEUPHORIA THERAPEUTICS INC (NEUP). This can be considered as Overvalued.
Can you provide the profitability details for NEUPHORIA THERAPEUTICS INC?
NEUPHORIA THERAPEUTICS INC (NEUP) has a profitability rating of 2 / 10.
Can you provide the expected EPS growth for NEUP stock?
The Earnings per Share (EPS) of NEUPHORIA THERAPEUTICS INC (NEUP) is expected to decline by -104017.17% in the next year.